Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A.
PRICE/FCF RATIO
N/A
Market Cap
$2.64B
Price/FCF Ratio
41.59
TTM Avg
92.02
3Y Avg
94.12
5Y Avg
94.12
Market Cap
$7.06B
Price/FCF Ratio
96.84
TTM Avg
83.72
3Y Avg
72.22
5Y Avg
72.22
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shoulder Innovations, Inc. (SI) | $468.68M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $440.37M | 19.92 | 29.57 | 30.20 | 30.38 |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.26B | 5.38 | 5.71 | 7.43 | 14.16 |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 41.59 | 92.02 | 94.12 | 94.12 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.76B | 27.43 | 23.55 | 21.72 | 20.30 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.06B | 96.84 | 83.72 | 72.22 | 72.22 |
| Oscar Health, Inc. (OSCR)vs › | $7.81B | 3.55 | 4.19 | 6.70 | 8.36 |
| Tempus AI, Inc. (TEM)vs › | $8.18B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.23B | 28.41 | 44.38 | 72.38 | 72.38 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
